BOSTON, May 31, 2022 -- Erbi Biosystems, Inc., a global leader in dose-scale, fully automated microbioreactors for cell therapy development and manufacturing, today announced the appointment of Brad Hamilton to…
foeglerJune 1, 2022
KTH Royal Institute of Technology, Karolinska University Hospital and Lund University partner with Erbi Biosystems to develop intensified bioprocesses, covering biologics, gene and cell therapies. BOSTON and STOCKHOLM, March 23,…
foeglerMarch 23, 2022
Manufacturers of the only commercially available mL-scale bioreactor with fully automated True Perfusion™ capability, has secured additional funding to expand its solutions for cell therapy development and manufacturing CAMBRIDGE, Mass., Jan.…
foeglerJanuary 4, 2022
This webcast features: Kevin Lee, Co-Founder, Principal Scientist, Erbi Biosystems The priority of speed to market is often at odds with issues around development resources, facility space, and infrastructure for both…
foeglerMay 4, 2021
WOBURN, Mass., Oct. 30, 2020 -- Erbi Biosystems, a transformative microfluidic bioprocess instrumentation company based on technology developed at MIT, announced today the closing of a finance round which brings the…
foeglerOctober 30, 2020
Scaled down models are becoming increasingly important to cell line and media development, as well as overall process optimization. These models provide the opportunity to run multiple experiments in parallel…
foeglerOctober 28, 2020
© 2022, Merck KGaA, Darmstadt Germany and / or its Affiliates. All rights reserved. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the US and Canada.
